List of all statistics in the 2013 Statistical bulletin

This pages provides a listing of all elements in the 2013 Statistical bulletin. Because of its size we recommend using the interactive version to browse the data set. Statistics in the list are organised by the categories listed below and you can use the links below to jump directly to the start of a category.

General polulation surveys (GPS)

• Table GPS-0. Nationwide surveys among the general population: bibliographic references
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (i) Survey methods.
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (ii) All adults (aged 15–64)
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (iii) Young adults (aged 15–34)
• Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (iv) Youth (15–24)
• Table GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (i) All adults (aged 15–64)
• Table GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (ii) Young adults (15–34)
• Table GPS-2. Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (iii) Youth (aged 15–24)
• Table GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (i) All adults (aged 15–64)
• Table GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (ii) Young adults (15–34)
• Table GPS-3. Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000
  Part (iii) Youth (aged 15–24)
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (i) All adults male (aged 15–64)
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (ii) All adults female (aged 15–64)
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (iii) Young adults male (aged 15–34)
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (iv) Young adults female (aged 15–34)
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (v) Youth male (aged 15–24)
• Table GPS-4. Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (vi) Youth female (aged 15–24)
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (i) All adults male (aged 15–64)
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (ii) All adults female (aged 15–64)
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (iii) Young adults male (aged 15–34)
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (iv) Young adults female (aged 15–34)
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (v) Youth male (aged 15–24)
• Table GPS-5. Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (vi) Youth female (aged 15–24)
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (i) All adults male (aged 15–64)
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (ii) All adults female (aged 15–64)
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (iii) Young adults male (aged 15–34)
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (iv) Young adults female (aged 15–34)
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (v) Youth male (aged 15–24)
• Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
  Part (vi) Youth female (aged 15–24)
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys
  Part (i) Survey methods
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys
  Part (ii) All adults (aged 15–64)
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys
  Part (iii) Young adults (aged 15–34)
• Table GPS-7. Lifetime prevalence of drug use in all available national general population surveys
  Part (iv) Youth (aged 15–24)
• Table GPS-8. Last 12 months prevalence of drug use in all available national general population surveys
  Part (i) All adults (aged 15–64)
• Table GPS-8. Last 12 months prevalence of drug use in all available national general population surveys
  Part (ii) Young adults (15–34)
• Table GPS-8. Last 12 months prevalence of drug use in all available national general population surveys
  Part (iii) Youth (aged 15–24)
• Table GPS-9. Last 30 days prevalence of drug use in all available national general population surveys
  Part (i) All adults (aged 15–64)
• Table GPS-9. Last 30 days prevalence of drug use in all available national general population surveys
  Part (ii) Young adults (15–34)
• Table GPS-9. Last 30 days prevalence of drug use in all available national general population surveys
  Part (iii) Youth (aged 15–24)
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys
  Part (i) All adults (aged 15–64), most recent data
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys
  Part (ii) All adults (aged 15–64), 2007 field trial
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys
  Part (iii) All adults (aged 15–64), 2004 field trial
• Table GPS-10. Frequency of use of cannabis amongst users in the last 30 days in national general population surveys
  Part (iv) Young adults (aged 15–34), combined sources
• Table GPS-121. Methodological information for nation-wide surveys among the general population
• Figure GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
• Figure GPS-2. Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-3. Last 30 days prevalence of cannabis use among youth (aged 15–24)
• Figure GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15–34)
  Part (i) All countries
• Figure GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15–34)
  Part (ii) Countries with three or more surveys
• Figure GPS-5. Last 12 months prevalence of amphetamines use among young adults (aged 15–34) and youth (aged 15–24)
• Figure GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
• Figure GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
• Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15–34)
  Part (i) All countries
• Figure GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15–34)
  Part (ii) Countries with three or more surveys
• Figure GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
  Part (i) All age groups
• Figure GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
  Part (ii) Males aged 15–24 in countries with high prevalence rates
• Figure GPS-10. Last 12 months prevalence of cannabis use by age group in UK (England and Wales)
• Figure GPS-11. Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-12. Last 12 months prevalence of cannabis use by age group
  Part (i) Selected EU-15 countries
• Figure GPS-12. Last 12 months prevalence of cannabis use by age group
  Part (ii) Selected 'new' EU countries
• Figure GPS-13. Last 12 months prevalence of cocaine use among young adults (aged 15–34) by gender
• Figure GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15–34)
  Part (i) All countries
• Figure GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15–34)
  Part (ii) Countries with three or more surveys
• Figure GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15–64), young adults (aged 15–34) and youth (aged 15–24)
• Figure GPS-16. Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)
• Figure GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34)
  Part (i) Cannabis use: lifetime experience, last 12 months and last 30 days prevalence
• Figure GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34)
  Part (ii) Cocaine, amphetamines and ecstasy use: lifetime experience, last 12 months and last 30 days prevalence
• Figure GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15–34) in Europe, Canada, Australia and the USA
• Figure GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15–34)
  Part (i) All countries
• Figure GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15–34)
  Part (ii) Countries with three or more surveys
• Figure GPS-22. Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use)
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)
  Part (i) UK (England and Wales)
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)
  Part (ii) Denmark
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)
  Part (iii) Germany
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)
  Part (iv) Spain
• Figure GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)
  Part (v) France

Problem drug use (PDU)

• Table PDU-0. Estimates of prevalence of problem drug use at national and subnational level: bibliographic references
• Table PDU-1. Estimates of prevalence of problem drug use at national level: summary table, 2006–11, rate per 1 000 aged 15–64
  Part (i) Overall problem drug use
• Table PDU-1. Estimates of prevalence of problem drug use at national level: summary table, 2006–11, rate per 1 000 aged 15–64
  Part (ii) Injecting drug use
• Table PDU-1. Estimates of prevalence of problem drug use at national level: summary table, 2006–11, rate per 1 000 aged 15–64
  Part (iii) Problem opioid use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2006–11 (rate per 1 000 population aged 15–64): Combined estimates per country
  Part (i) Estimated trends of overall problem drug use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2006–11 (rate per 1 000 population aged 15–64): Combined estimates per country
  Part (ii) Estimated trends of problem opioid use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2006–11 (rate per 1 000 population aged 15–64): Combined estimates per country
  Part (iii) Estimated trends of injecting drug use
• Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2006–11 (rate per 1 000 population aged 15–64): Combined estimates per country
  Part (iv) Estimated trends of problem stimulant use
• Table PDU-102. Prevalence of problem drug use at national level (full listing of studies)
  Part (i) Problem drug use
• Table PDU-102. Prevalence of problem drug use at national level (full listing of studies)
  Part (ii) Injecting drug use
• Table PDU-103. Prevalence of problem drug use at sub-national level (full list of studies)
  Part (i) Problem drug users
• Table PDU-103. Prevalence of problem drug use at sub-national level (full list of studies)
  Part (ii) Injecting drug users
• Table PDU-104. Trends in injecting drug use: percentage currently injecting among all clients entering treatment for primary drug heroin, 2005–11
• Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15–64), 2006–11 (last study available)
  Part (i) Estimates of overall problem drug use
• Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15–64), 2006–11 (last study available)
  Part (ii) Estimates of problem opioid use
• Figure PDU-2. Estimates of the prevalence of injecting drug use (rate per 1 000 population aged 15–64), 2006–11 (last study available)

Treatment demand (TDI)

• Table TDI-1. Clients entering treatment and treatment units by country, 2011 or most recent year available
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998–2011
  Part (i) New clients by country and year of treatment
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998–2011
  Part (ii) All clients by country and year of treatment
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998–2011
  Part (iii) Reporting treatment units by country and year of treatment
• Table TDI-2. Clients entering treatment and reporting treatment units, 1998–2011
  Part (iv) Types of reporting treatment unit by country
• Table TDI-3. New clients entering treatment by primary drug, 1998–2011
  Part (i) New heroin clients by country and year of treatment (%)
• Table TDI-3. New clients entering treatment by primary drug, 1998–2011
  Part (ii) New cocaine clients by country and year of treatment (%)
• Table TDI-3. New clients entering treatment by primary drug, 1998–2011
  Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
• Table TDI-3. New clients entering treatment by primary drug, 1998–2011
  Part (iv) New cannabis clients by country and year of treatment (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2011 or most recent year available
  Part (i) New clients by country and gender (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2011 or most recent year available
  Part (ii) All clients by country and gender (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2011 or most recent year available
  Part (iii) New clients by country and age (%)
• Table TDI-4. Demographic characteristics of clients entering treatment, 2011 or most recent year available
  Part (iv) All clients by country and age (%)
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2011 or most recent year available
  Part (i) New clients by country and primary drug (%), regardless whether they inject the drug
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2011 or most recent year available
  Part (ii) All clients by country and primary drug (%), regardless whether they inject the drug
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2011 or most recent year available
  Part (iii) New clients by country and rates of injection of primary drug (%)
• Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2011 or most recent year available
  Part (iv) All clients by country and rates of injection of primary drug (%)
• Table TDI-6. Incidence of treatment demand for drug use, new clients, 2011 or most recent year available
• Table TDI-7. Data coverage, 2011 or most recent year available
  Part (i) Clients entering treatment by country and type of treatment centre and type of client
• Table TDI-7. Data coverage, 2011 or most recent year available
  Part (ii) Units by country and type of treatment centre and reporting status
• Table TDI-8. Primary use of stimulants of clients entering treatment, 2011 or most recent year available
  Part (i) New clients by country and type of stimulant (%)
• Table TDI-8. Primary use of stimulants of clients entering treatment, 2011 or most recent year available
  Part (ii) All clients by country and type of stimulant (%)
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and gender
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and gender
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2011 or most recent year available
  Part (iii) New outpatient clients by country and age
• Table TDI-9. Demographic characteristics of clients entering outpatient treatment, 2011 or most recent year available
  Part (iv) All outpatient clients by country and age
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (i) Age distribution, New outpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (ii) Drug distribution, New outpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (iii) Age distribution, All outpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (iv) Drug distribution, All outpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (v) Age distribution, New inpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (vi) Drug distribution, New inpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (vii) Age distribution, All inpatient clients (%)
• Table TDI-10. Primary drug and age. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (viii) Drug distribution, All inpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (i) Age at first use distribution, New outpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (ii) Drug distribution, New outpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (iii) Age at first use distribution, All outpatient clients(%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (iv) Drug distribution, All outpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (v) Age at first use distribution, New inpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (vi) Drug distribution, New inpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (vii) Age at first use distribution, All inpatient clients (%)
• Table TDI-11. Age at first use and primary drug. EU, Croatia, Norway and Turkey, 2011 or most recent year available
  Part (viii) Drug distribution, All inpatient clients (%)
• Table TDI-12. Education status of clients entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and education status (%)
• Table TDI-12. Education status of clients entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and education status (%)
• Table TDI-12. Education status of clients entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients by country and education status (%)
• Table TDI-12. Education status of clients entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients by country and education status (%)
• Table TDI-13. Labour status of clients entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and labour status (%)
• Table TDI-13. Labour status of clients entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and labour status (%)
• Table TDI-13. Labour status of clients entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients by country and labour status (%)
• Table TDI-13. Labour status of clients entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients by country and labour status (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and with whom living (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and with whom living (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients by country and with whom living (%)
• Table TDI-14. Persons with whom client is living on entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients by country and with whom living (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2011 or most recent year available
  Part (i) New clients entering outpatient treatment by country and type of accommodation (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2011 or most recent year available
  Part (ii) All clients entering outpatient treatment by country and type of accommodation (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2011 or most recent year available
  Part (iii) New clients entering inpatient treatment by country and type of accommodation (%)
• Table TDI-15. Type of accommodation of clients entering treatment, 2011 or most recent year available
  Part (iv) All clients entering inpatient treatment by country and type of accommodation (%)
• Table TDI-16. Source of referral of clients entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and source of referral (%)
• Table TDI-16. Source of referral of clients entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and source of referral (%)
• Table TDI-16. Source of referral of clients entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients by country and source of referral (%)
• Table TDI-16. Source of referral of clients entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients by country and source of referral (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (i) New opioid outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (ii) All opioid outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (iii) New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (iv) All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (ix) New cannabis outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (v) New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (vi) All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (vii) New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration (%)
• Table TDI-17. Route of administration by primary drug of clients entering treatment, 2011 or most recent year available
  Part (x) All cannabis outpatient clients by country and usual route of administration (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients by primary drug and frequency of use (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by primary drug and frequency of use (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients by primary drug and frequency of use (%)
• Table TDI-18. Frequency of use of primary drug of clients entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients by primary drug and frequency of use (%)
• Table TDI-19. Primary drug of clients entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and primary drug (%)
• Table TDI-19. Primary drug of clients entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and primary drug (%)
• Table TDI-19. Primary drug of clients entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients by country and primary drug (%)
• Table TDI-19. Primary drug of clients entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients by country and primary drug (%)
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2011 or most recent year available
  Part (i) New outpatient clients, ratio of males to females by country and primary drug
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2011 or most recent year available
  Part (ii) All outpatient clients, ratio of males to females by country and primary drug
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2011 or most recent year available
  Part (iii) New inpatient clients, ratio of males to females by country and primary drug
• Table TDI-21. Gender ratio by primary drug of clients entering treatment, 2011 or most recent year available
  Part (iv) All inpatient clients, ratio of males to females by country and primary drug
• Table TDI-22. Secondary drugs cited by clients entering treatment, 2011 or most recent year available
  Part (i) Outpatient units
• Table TDI-22. Secondary drugs cited by clients entering treatment, 2011 or most recent year available
  Part (ii) Inpatient units
• Table TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2011 or most recent year available
  Part (i) New clients by country and primary drug and type of treatment centre (%)
• Table TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2011 or most recent year available
  Part (ii) All clients by country and primary drug and type of treatment centre (%)
• Table TDI-25. Age distribution of all clients entering outpatient treatment by primary drug and gender, 2011 or most recent year available
• Table TDI-32. Mean age of clients entering treatment by primary drug and gender, 2011 or most recent year available
  Part (i) Outpatient clients
• Table TDI-32. Mean age of clients entering treatment by primary drug and gender, 2011 or most recent year available
  Part (ii) Inpatient clients
• Table TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2011 or most recent year available
  Part (i) Outpatient units
• Table TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2011 or most recent year available
  Part (ii) Inpatient units
• Table TDI-36. Primary amphetamine use among new clients entering treatment (%), 2006–11
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2011 or most recent year available
  Part (i) All clients by country and primary drug and type of treatment unit
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2011 or most recent year available
  Part (ii) Outpatient clients by primary drug and mean age, gender ratio
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2011 or most recent year available
  Part (iii) Inpatient clients by primary drug and mean age, gender ratio
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2011 or most recent year available
  Part (iv) Outpatient clients by secondary drug and primary drug
• Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2011 or most recent year available
  Part (v) Inpatient clients by secondary drug and primary drug
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (i) New opioid outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iii) New stimulants (other than cocaine) outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iv) New hallucinogen outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (v) New hypnotics and sedatives outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vi) New volatile inhalant outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vii) New cannabis outpatient clients by country and age
• Table TDI-102. New clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (viii) New 'other drugs' outpatient clients by country and by age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (i) All opioid outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iii) All stimulants (other than cocaine) outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iv) All hallucinogen outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (v) All hypnotics and sedatives outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vi) All volatile inhalant outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vii) All cannabis outpatient clients by country and age
• Table TDI-103. All clients entering outpatient treatment by primary drug and age, 2011 or most recent year available
  Part (viii) All 'other drugs' outpatient clients by country and by age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (i) New opioid inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iii) New stimulants (other than cocaine) inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iv) New hallucinogen inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (v) New hypnotics and sedatives inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vi) New volatile inhalants inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vii) New cannabis inpatient clients by country and age
• Table TDI-104. New clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (viii) New 'other drugs' inpatient clients by country and by age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (i) All opioid inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iii) All stimulants (other than cocaine) inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (iv) All hallucinogen inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (v) All hypnotics and sedatives inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vi) All volatile inhalant inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (vii) All cannabis inpatient clients by country and age
• Table TDI-105. All clients entering inpatient treatment by primary drug and age, 2011 or most recent year available
  Part (viii) All 'other drugs' inpatient clients by country and by age
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (i) New opioid outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iii) New stimulants (other than cocaine) outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iv) New hallucinogen outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (v) New hypnotics and sedatives outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vi) New volatile inhalant outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vii) New cannabis outpatient clients by country and age at first use
• Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
  Part (viii) New 'other drugs' outpatient clients by country and by age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (i) All opioid outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iii) All stimulants (other than cocaine) outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iv) All hallucinogen outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (v) All hypnotics and sedatives outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vi) All volatile inhalant outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vii) All cannabis outpatient clients by country and age at first use
• Table TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (viii) All 'other drugs' outpatient clients by country and by age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (i) New opioid inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iii) New stimulants (other than cocaine) inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iv) New hallucinogen inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (v) New hypnotics and sedatives inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vi) New volatile inhalant inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vii) New cannabis inpatient clients by country and age at first use
• Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (viii) New 'other drugs' inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (i) All opioid inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iii) All stimulants (other than cocaine) inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (iv) All hallucinogen inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (v) All hypnotics and sedatives inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vi) All volatile inhalant inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (vii) All cannabis inpatient clients by country and age at first use
• Table TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available
  Part (viii) All 'other drugs' inpatient clients by country and age at first use
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (i) New opioid outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (ii) All opioid outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (iii) New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (iv) All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (v) New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (vi) All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (vii) New cannabis outpatient clients by country and frequency of use (%)
• Table TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2011 or most recent year available
  Part (viii) All cannabis outpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (i) New opioid inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (ii) All opioid inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (iii) New cannabis inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (iv) All cannabis inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (v) New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (vi) All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (vii) New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
• Table TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2011 or most recent year available
  Part (viii) All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
• Table TDI-113. All clients entering treatment for opioids by country and type of opioid misused (%), 2011 or most recent year available
• Table TDI-114. Primary opioids distribution among all clients entering treatment by country and type of treatment centre (%), 2011
• Table TDI-115. HCL and Crack use of clients entering outpatient treatment, 2011 or most recent year available
  Part (i) New outpatient clients by country and type of cocaine product
• Table TDI-115. HCL and Crack use of clients entering outpatient treatment, 2011 or most recent year available
  Part (ii) All outpatient clients by country and type of cocaine product
• Figure TDI-1. Trend in estimated number of new clients entering treatment by selected primary drugs, 2006–11
  Part (i) Percentage by primary drug
• Figure TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2006–11
  Part (ii) Numbers of clients by primary drug
• Figure TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2011.
  Part (i) New clients
• Figure TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2011.
  Part (ii) All clients
• Figure TDI-3. Trend in estimated number of all clients entering treatment by selected primary drug used, 2006–11
  Part (i) Percentage by primary drug
• Figure TDI-3. Trend in estimated number of all clients entering treatment by selected primary drugs, 2006–2011
  Part (ii) Numbers of clients by primary drugHeroinCocaineCannabisOther stimulantsOther drugsNot known / missing
• Figure TDI-7. New outpatient clients injecting opioid as primary drug in 18 countries supplying data, 2006–11

Drug-related deaths (DRD)

• Table DRD-0. Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
• Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
  Part (i) Demographic characteristics, 2011 or last year with available information
• Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
  Part (ii) Numbers of drug-induced deaths and toxicology, 2011 or last year with available information
• Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
  Part (iii) Demographic characteristics and toxicology, 1990 or earliest year with available information
• Table DRD-2. Number of drug-induced deaths recorded in EU according to national definitions
  Part (i) Total drug-induced deaths, 1995–2011
• Table DRD-2. Number of drug-induced deaths recorded in EU according to national definitions
  Part (ii) Male drug-induced deaths, 1995–2011
• Table DRD-2. Number of drug-induced deaths recorded in EU according to national definitions
  Part (iii) Female drug-induced deaths, 1995–2011
• Table DRD-2. Number of drug-induced deaths recorded in EU according to national definitions
  Part (iv) Total drug-induced deaths under the age of 25 years, 1995–2011
• Table DRD-2. Number of drug-induced deaths recorded in EU according to national definitions
  Part (v) Totals and indexes, 1995–2011
• Table DRD-3. Number of drug-induced deaths recorded in EU and Norway according to EMCDDA standard definition 'Selection B', 1995–2011
• Table DRD-4. Number of drug-induced deaths recorded in EU according to EMCDDA standard definition 'Selection D', 1995–2011
• Table DRD-5. Mortality due to drug-induced deaths in EU, Croatia, Turkey and Norway, in all adults and adults aged 15–39 years (total and males)
  Part (i) Population mortality rates, 2011 or last year with available information
• Table DRD-5. Mortality due to drug-induced deaths in EU, Croatia, Turkey and Norway, in all adults and adults aged 15–39 years (total and males)
  Part (ii) Proportional mortality due to drug-induced deaths, 2010 or last year with available information.
• Table DRD-5. Mortality due to drug-induced deaths in EU, Croatia, Turkey and Norway, in all adults and adults aged 15–39 years (total and males)
  Part (iii) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
• Table DRD-106. Methodological features of drug-induced deaths reported by National Reitox Focal Points (based on national definitions,Reitox Standard Table 5)
• Table DRD-107. Number of drug-induced deaths recorded in EU according to national definitions
  Part (i) Total drug-induced deaths, 1985–2011
• Table DRD-107. Number of drug-induced deaths recorded in EU according to national definitions
  Part (ii) Totals and indexes, 1985–2011
• Table DRD-108. Drug-induced deaths: detailed qualitative national information on deaths due to specific substances in EU (2012 National Reports and information based on toxicological findings submitted in Standard Table 5)
• Figure DRD-1. Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
• Figure DRD-2. Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported
• Figure DRD-3. Trends in mean age of drug-induced deaths in some of the EU-15, 1990–2011
• Figure DRD-4. Trends in mean age of drug-induced deaths in some new EU Member States, 1990–2011
• Figure DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
  Part (i) Indexed trend in the EU-15 and Norway 1990–2010
• Figure DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
  Part (ii) Indexed trend in the new Member States, 1996–2010
• Figure DRD-6. Indexed overall trends for males and females in drug-induced deaths in the EU-15 and Norway, 1990–2010
• Figure DRD-7. Mortality due to drug-induced deaths among all adults (15-64 years) in EU, Norway, Croatia and Turkey for the most recent year reported
  Part (i) Mortality rates per million among all adults (15–64 years) due to drug-related deaths
• Figure DRD-7. Mortality due to drug–induced deaths among all adults (15–64 years) in EU, Norway, Croatia and Turkey for the most recent year reported
  Part (ii) Mortality rates among all adults (15–64 years) due to drug–related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use
• Figure DRD-8. Indexed long term trend in drug-induced deaths in the EU-15 and Norway, 1985–10
• Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the EU, 1990–2011 (three-year moving average)
  Part (i) Selected EU Member States and Norway, 1990–2011
• Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the EU, 1990–2011 (three-year moving average)
  Part (ii) Selected EU Member States, 1990–2011
• Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the EU, 1990–2011 (three-year moving average)
  Part (iii) Seleted EU countries, 1990–2011
• Figure DRD-10. Mean age of drug-induced deaths in EU, last year with available data
• Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole.
  Part (i) Index in selected Member States, 1985–2011
• Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole.
  Part (ii) Index in selected Member States, 1985–2011
• Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole.
  Part (iii) Index in selected Member States, 1985–2011
• Figure DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU, Croatia and Norway
  Part (i) Changes between 2000 and 2003
• Figure DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU, Croatia and Norway
  Part (ii) Changes between 2003 and 2010/11
• Figure DRD-13. Number of drug-induced deaths recorded in EU occurring under the age of 25 according to national definitions
  Part (i) EU-15 and Norway 1990–2010
• Figure DRD-13. Number of drug-induced deaths recorded in EU occurring under the age of 25 according to national definitions
  Part (ii) New Member States, 1990–2010

Drug-related infectious diseases (INF)

• Table INF-0. Bibliographic references
  Part (i) References for prevalence data
• Table INF-0. Bibliographic references
  Part (ii) References for notifications data
• Table INF-1. Prevalence of HIV infection among injecting drug users in the EU, Croatia, Turkey and Norway, 2011 or most recent year available (summary table by country)
• Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU, Croatia, Turkey and Norway, 2011 or most recent year available (summary table by country)
• Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, Croatia, Turkey and Norway, 2011 or most recent year available (summary table by country)
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (i) HIV infection in the EU, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (ii) HIV infection in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (iii) AIDS incidence in the EU, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-104. HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
  Part (iv) AIDS incidence in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes
• Table INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU, Croatia, Turkey and Norway
  Part (i) Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor
• Table INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU, Croatia, Turkey and Norway
  Part (ii) Case definitions
• Table INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU, Croatia, Turkey and Norway
  Part (i) Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor
• Table INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU, Croatia, Turkey and Norway
  Part (ii) Case definitions
• Table INF-108. Prevalence of HIV infection among injecting drug users (%) in EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-109. Prevalence of HIV infection among injecting drug users under age 25 (%) in EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-110. Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%) in EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-111. Prevalence of hepatitis C infection among injecting drug users (%) in EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-112. Prevalence of hepatitis C infection among injecting drug users under age 25 (%) EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-113. Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%) in EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-114. Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg) in EU, Croatia, Turkey and Norway, 1991–2011
• Table INF-115. Prevalence of antibodies against hepatitis B virus among injecting drug users (%) in EU, Croatia, Turkey and Norway, 1991–2011
• Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998–11
  Part (i) EU, Croatia, Turkey and Norway
• Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998–2011
  Part (ii) Non-EU countries of the WHO European region
• Figure INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2006–11.
  Part (i) EU, Croatia, Turkey and Norway: five highest countries in peak value 2006–11
• Figure INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2006–11.
  Part (ii) EU, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2006–11
• Figure INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2006–11.
  Part (iii) Non-EU countries of WHO European region with over 50 cases per million population in peak value 2006–11
• Figure INF-2. HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2006–11.
  Part (iv) Non-EU countries of WHO European region with 10 to 50 cases per million population in peak value 2006–11
• Figure INF-3. HIV prevalence among injecting drug users: studies with national and sub-national coverage
  Part (i) All injecting drug users, 2010–11
• Figure INF-3. HIV prevalence among injecting drug users: studies with national and subnational coverage
  Part (ii) Young injecting drug users (under age 25), 2010–11
• Figure INF-3. HIV prevalence among injecting drug users: studies with national and sub-national coverage
  Part (iii) New injecting drug users (injecting less than 2 years), 2010–11
• Figure INF-6. HCV antibody prevalence among injecting drug users: studies with national and sub-national coverage.
  Part (i) All injecting drug users, 2010–11
• Figure INF-6. HCV antibody prevalence among injecting drug users: studies with national and sub-national coverage
  Part (ii) Young injecting drug users (under age 25), 2010–11
• Figure INF-6. HCV antibody prevalence among injecting drug users: studies with national and sub-national coverage
  Part (iii) New injecting drug users (injecting less than 2 years), 2010–11
• Figure INF-9. Prevalence of markers of HBV infection among injecting drug users: studies with national and sub-national coverage
  Part (i) Percentage ever infected (positive for aHBc), 2010–11
• Figure INF-9. Prevalence of markers of HBV infection among injecting drug users: studies with national and sub-national coverage
  Part (ii) Percentage with current infection (positive for HBsAg), 2010–11

Youth and the schools population (EYE)

• Table EYE-0. School surveys: Sources
• Table EYE-8. HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old
• Table EYE-9. HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
  Part (i) All students
• Table EYE-9. HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
  Part (ii) Males
• Table EYE-9. HBSC school surveys (2009/10) percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
  Part (iii) Females
• Table EYE-10. Recent school surveys (2005–12): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
• Table EYE-11. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years
• Table EYE-20. ESPAD 2011 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (i) All students
• Table EYE-20. ESPAD 2011 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (ii) Males
• Table EYE-20. ESPAD 2011 school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (iii) Females
• Table EYE-21. ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
  Part (i) All students
• Table EYE-21. ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
  Part (ii) Males
• Table EYE-21. ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
  Part (iii) Females
• Table EYE-22. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (i) All students
• Table EYE-22. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (ii) Males
• Table EYE-22. All ESPAD school surveys: lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
  Part (iii) Females
• Table EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
  Part (i) All students
• Table EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
  Part (ii) Males
• Table EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
  Part (iii) Females
• Table EYE-30. Recent school surveys (2003–12): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17–18 years old
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (i) Decreasing lifetime prevalence of cannabis use among 15–16 year old school students over the five rounds of the ESPAD survey
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (ii) Stable lifetime prevalence of cannabis use among 15–16 year old school students over the five rounds of the ESPAD survey
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (iii) Increases in lifetime prevalence of cannabis use among 15–16 year old school students over the five rounds of the ESPAD survey
• Figure EYE-1. Cannabis prevalence rates, ESPAD 2011
  Part (iv) Comparison of lifetime prevalence of cannabis use with perceived great risk (percentages), among 15–16 year old school students in 2007–11

Drug law offences (DLO)

• Table DLO-0. Drug law offences
  Part (i) Data source: name of institution and name of monitoring system/study
• Table DLO-0. Drug law offences
  Part (ii) Methodological comments
• Table DLO-0. Drug law offences
  Part (iii) Terminology used in defining drug law offences in Europe
• Table DLO-1. Drug law offences, 1995–2011
  Part (i) Number of reports of offences
• Table DLO-1. Drug law offences, 1995–2011
  Part (ii) Number of reports of persons
• Table DLO-1. Drug law offences, 1995–2011
  Part (iii) Methodological notes
• Table DLO-2. Offence types in reports for drug law offences, 2010 or 2011
  Part (i) Number and percentage of all reports for drug law offences
• Table DLO-2. Offence types involved in reports for drug law offences: methods of percentages calculation for drug law offences
  Part (ii) Methodological notes
• Table DLO-3. Drug types in reports for drug law offences, 2010 or 2011
  Part (i) Number and percentage of all reports for drug law offences
• Table DLO-3. Drug types in reports for drug law offences
  Part (ii) Methodological notes
• Table DLO-4. Drug law offences related to drug use or possession for use, 2003–11
  Part (i) Number and percentage
• Table DLO-4. Drug law offences related to drug use or possession for use, 2003–11
  Part (ii) Methodological notes
• Table DLO-5. Drug law offences related to drug supply, 2003–11
  Part (i) Number and percentage
• Table DLO-5. Drug law offences related to drug supply, 2003–11
  Part (ii) Methodological notes
• Table DLO-6. Cannabis-related offences, 2003–11
  Part (i) Number and percentage of all drug law offences
• Table DLO-6. Cannabis-related offences, 2003–11
  Part (ii) Methodological notes
• Table DLO-7. Heroin-related offences, 2003–11
  Part (i) Number and percentage of all drug law offences
• Table DLO-7. Heroin-related offences, 2003–11
  Part (ii) Methodological notes
• Table DLO-8. Cocaine-related offences, 2003–11
  Part (i) Number and percentage of all drug law offences
• Table DLO-8. Cocaine-related offences, 2003–11
  Part (ii) Methodological notes
• Table DLO-109. Number of reports for drug law offences, 1985–2011
  Part (i) Number of reports of offences
• Table DLO-109. Number of reports for drug law offences, 1985–2011
  Part (ii) Number of reports of persons
• Table DLO-109. Number of reports for drug law offences, 1985–2011
  Part (iii) Methodological notes
• Figure DLO-1. Indexed trends in reports for drug-related offences by broad type of offence in the EU , 2006–11
• Figure DLO-2. Offence types in reports for drug law offences in the EU, Croatia and Norway, 2010 or 2011
• Figure DLO-3. Indexed trends in reports for drug law offences by type of drug in the EU, 2006–11
• Figure DLO-4. Indexed trends in reports for offences related to drug use or possession for use in the EU, 2006–11
• Figure DLO-5. Indexed trends in reports for offences related to drug supply in the EU, 2006–11

Drug use in prison (DUP)

• Table DUP-0. Prevalence of drug use among prisoners: sources and bibliographic references
• Table DUP-1. Prevalence of lifetime drug use among prisoners, 2000–11
  Part (i) Most recent data available from survey/routine monitoring (%)
• Table DUP-1. Prevalence of lifetime drug use among prisoners, 2000–11
  Part (ii) Methodological notes
• Table DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–11
  Part (i) Most recent data available from survey/routine monitoring (%)
• Table DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–11
  Part (ii) Methodological notes
• Table DUP-3. Prevalence of drug use within prison among prisoners, 2000–11
  Part (i) Most recent data available from survey/routine monitoring (%)
• Table DUP-3. Prevalence of drug use within prison among prisoners, 2000–11
  Part (ii) Methodological Notes
• Table DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–11
  Part (i) Most recent data available from survey/routine monitoring (%)
• Table DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–11
  Part (ii) Methodological notes
• Table DUP-105. Prevalence (percentage) of drug use among prisoners in EU and Norway (full listing of studies)

Health and social responses (HSR)

• Table HSR-1. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine
• Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU, Croatia, Turkey and Norway
  Part (i) Legal framework regarding the initiation of OST by substitution medication
• Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU, Croatia, Turkey and Norway
  Part (ii) Legal framework regarding the continuation of OST by substitution medication
• Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU, Croatia, Turkey and Norway
  Part (iii) Legal framework regarding the dispensing of substitution medications
• Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
  Part (i) Estimates of clients in methadone treatment or any opioid substitution in EU, Croatia, Turkey and Norway, 1993–2011
• Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
  Part (ii) Estimates and share of clients in methadone (MMT) and buprenorphine-based opioid substitution treatment in EU, Croatia, Turkey and Norway in 2011 or latest available year
• Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
  Part (iii) Methodological notes EU, Croatia, Turkey and Norway, 2003–11
• Table HSR-4. Needle and syringe programmes (NSPs)
  Part (i) Year of introduction of needle and syringe programmes (NSPs), types of programmes available in 2011 and number of sites
• Table HSR-4. Needle and syringe programmes (NSPs)
  Part (ii) NSP geographical coverage, 2011 or latest available year
• Table HSR-5. Provision of needle and syringe programmes (NSPs)
  Part (i) Syringes provided through needle and syringe programmes (NSPs), 2003–11
• Table HSR-5. Provision of needle and syringe programmes (NSPs)
  Part (ii) Clients and contacts at specialist NSP agencies, 2010–11
• Table HSR-6. Hepatitis responses in the EU, Croatia, Turkey and Norway
  Part (i) Hepatitis B immunization
• Table HSR-6. Hepatitis responses in the EU, Croatia, Turkey and Norway
  Part (ii) Availability of Hepatitis C testing
• Table HSR-7. Availability of selected health responses in prison in EU, Croatia, Turkey and Norway
• Table HSR-8. Responses to drug related deaths in Europe
  Part (i) Availability of selected responses to reduce drug related deaths in the EU, Norway and Turkey (expert ratings)
• Table HSR-8. Responses to drug related deaths in Europe
  Part (ii) Availability of information material on drug-related deaths and emergencies for specific target groups in the EU, Norway and Turkey
• Table HSR-9. Opioid substitution treatment in prison in EU, Croatia, Turkey and Norway, 2010/2011
• Table HSR-10. Estimation of the total number of clients in treatment in 2011 or latest available year
• Figure HSR-1. Opioid substitution treatment coverage
  Part (i) Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2011 or most recent year available
• Figure HSR-1. Opioid substitution treatment coverage
  Part (ii) Overall estimated number of problem opioid users in treatment (in opioid substitution treatment and other treatments) as a percentage of the estimated number of problem opioid users, 2011 or most recent year available
• Figure HSR-2. Estimated number of clients in opioid substitution treatment (OST) in EU-15 and EU-12, 1993–2011.
• Figure HSR-3. Syringes distributed through specialised programmes per estimated IDU in 2011 or latest available year
• Figure HSR-4. Proportion of prison population receiving opioid substitution treatment (OST) on a given day in 2011 or latest available year

Seizures data (SZR)

• Table SZR-0. Seizures of illicit drugs
  Part (i) Data source: name of institution and name of monitoring system/study
• Table SZR-0. Seizures of illicit drugs
  Part (ii) Methodological comments
• Table SZR-1. Number of cannabis resin seizures, 1995–2011
• Table SZR-2. Quantities (kg) of cannabis resin seized, 1995–2011
• Table SZR-3. Number of herbal cannabis seizures, 1995–2011
• Table SZR-4. Quantities (kg) of herbal cannabis seized, 1995–2011
• Table SZR-5. Number of seizures of cannabis plants, 1995–2011
• Table SZR-6. Quantities of cannabis plants seized, 1995–2011
  Part (i) Number of plants, 1995–2011
• Table SZR-6. Quantities of cannabis plants seized, 1995–2011
  Part (ii) Kilograms of plants, 1995–2011
• Table SZR-7. Number of heroin seizures,1995–2011
• Table SZR-8. Quantities (kg) of heroin seized, 1995–2011
• Table SZR-9. Number of cocaine seizures, 1995–2011
• Table SZR-10. Quantities (kg) of cocaine seized, 1995–2011
• Table SZR-11. Number of amphetamine seizures, 1995–2011
• Table SZR-12. Quantities of amphetamine seized, 1995–2011
  Part (i) Kilograms of amphetamine
• Table SZR-12. Quantities of amphetamine seized, 1995–2011
  Part (ii) Number of tablets of amphetamine
• Table SZR-13. Number of ecstasy seizures, 1995–2011
• Table SZR-14. Quantities of ecstasy seized, 1995–2011
  Part (i) Number of tablets of ecstasy
• Table SZR-14. Quantities of ecstasy seized, 1995–2011
  Part (ii) Kilograms of ecstasy
• Table SZR-15. Number of LSD seizures, 1995–2011
• Table SZR-16. Quantities (units) of LSD seized, 1995–2011
• Table SZR-17. Number of methamphetamine seizures, 2001–11
• Table SZR-18. Quantities (kg) of methamphetamine seized 2001–11
• Table SZR-19. Number of crack cocaine seizures, 1995–2011
• Table SZR-20. Quantities (kg) of crack cocaine seized 1995–2011
• Table SZR-21. Other substances seized, not included in other SZR tables, 2004–11
• Figure SZR-1. Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2006–11
• Figure SZR-2. Estimated number of cocaine seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2006–11

Price and purity information (PPP)

• Table PPP-1. Price of cannabis products at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal price in Euros
• Table PPP-1. Price of cannabis products at retail level, 2011
  Part (ii) Sources of information
• Table PPP-1. Price of cannabis products at retail level, 2011
  Part (iii) Geographical coverage / methodology
• Table PPP-2. Price of heroin at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal price in Euros
• Table PPP-2. Price of heroin at retail level, 2011
  Part (ii) Sources of information
• Table PPP-2. Price of heroin at retail level, 2011
  Part (iii) Geographical coverage / methodology
• Table PPP-3. Price of cocaine products at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal price in Euros
• Table PPP-3. Price of cocaine products at retail level, 2011
  Part (ii) Sources of information
• Table PPP-3. Price of cocaine products at retail level, 2011
  Part (iii) Geographical coverage / methodology
• Table PPP-4. Price of synthetic drugs at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal price in Euros
• Table PPP-4. Price of synthetic drugs at retail level, 2011
  Part (ii) Sources of information
• Table PPP-4. Price of synthetic drugs at retail level, 2011
  Part (iii) Geographical coverage / Methodology
• Table PPP-5. Potency of cannabis products at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content
• Table PPP-5. Potency of cannabis products at retail level, 2011
  Part (ii) Sources of information
• Table PPP-5. Potency of cannabis products at retail level, 2011
  Part (iii) Geographical coverage / sampling frame / type of study
• Table PPP-6. Purity of heroin at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
• Table PPP-6. Purity of heroin at retail level, 2011
  Part (ii) Sources of information
• Table PPP-6. Purity of heroin at retail level, 2011
  Part (iii) Geographical coverage / sampling frame / type of study / purity determined to base-salt
• Table PPP-7. Purity of cocaine products at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
• Table PPP-7. Purity of cocaine products at retail level, 2011
  Part (ii) Sources of information
• Table PPP-7. Purity of cocaine products at retail level, 2011
  Part (iii) Geographical coverage / sampling frame / type of study / purity determined to base-salt
• Table PPP-8. Purity of synthetic drugs at retail level, 2011
  Part (i) Minimum, maximum, mean, median and modal purity recorded
• Table PPP-8. Purity of synthetic drugs at retail level, 2011
  Part (ii) Sources of information
• Table PPP-8. Purity of synthetic drugs at retail level, 2011
  Part (iii) Geographical coverage / sampling frame / type of study
• Table PPP-9. Composition of illicit drug tablets, 2011
  Part (i) Content of synthetic scheduled illicit drugs
• Table PPP-9. Composition of illicit drug tablets, 2011
  Part (ii) Sources of information
• Table PPP-9. Composition of illicit drug tablets, 2011
  Part (iii) Sampling frame / type of monitoring system
• Table PPP-9. Composition of illicit drug tablets, 2011
  Part (iv) Information available on substances listed in categories 'Miscellaneous' and 'Other'
• Table PPP-9. Composition of illicit drug tablets, 2011
  Part (v) Information available on adulterants, cutting agents and/or impurities
• Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2006–11
• Figure PPP-2. Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2006–11